Table 1 Distributions of the factors investigated for potential associations with survival
From: Prognostic factors and a new scoring system for survival of patients irradiated for bone metastases
N patients (%) | |
|---|---|
Age | |
≤ 60 years | 132 (30) |
61–70 years | 131 (29) |
> 70 years | 182 (41) |
Gender | |
Female | 226 (51) |
Male | 219 (49) |
Karnofsky performance score | |
≤ 70 | 165 (37) |
80–100 | 237 (53) |
Unknown | 43 (10) |
Type of primary tumor | |
Breast cancer | 125 (28) |
Prostate cancer | 59 (13) |
Lung cancer | 138 (31) |
Renal cell carcinoma | 24 (5) |
Colorectal cancer | 20 (4) |
Other tumors | 79 (18) |
Interval between cancer diagnosis and RT of bone metastases | |
≤ 8 months | 226 (51) |
≥ 9 months | 219 (49) |
Visceral metastases at the time of RT | |
No | 187 (42) |
Yes | 258 (58) |
Other (non-irradiated) bone metastases at the time of RT | |
No | 109 (24) |
Yes | 334 (75) |
Unknown | 2 (< 1) |
Location of irradiated bone metastases | |
Spinal site(s) only | 170 (38) |
Extraspinal site(s) with or without spinal site(s) | 275 (62) |
Number of irradiated sites | |
Single | 186 (42) |
Multiple | 259 (58) |
Pathological fracture | |
No | 309 (69) |
Yes | 136 (31) |
Pre-RT surgery (no vs. yes) | |
No | 347 (78) |
Yes | 96 (22) |
Unknown | 2 (< 1) |
Pre-RT administration of bisphosphonates/denosumab | |
No | 268 (60) |
Yes | 167 (38) |
Unknown | 10 (2) |
Pre-RT systemic anticancer treatment | |
No | 127 (29) |
Yes | 317 (71) |
Unknown | 1 (< 1) |
Fractionation of RT | |
Short-course RT | 43 (10) |
Longer-course RT | 402 (90) |